242 related articles for article (PubMed ID: 21124329)
1. Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways.
Takayama N; Kai H; Kudo H; Yasuoka S; Mori T; Anegawa T; Koga M; Kajimoto H; Hirooka Y; Imaizumi T
Hypertens Res; 2011 Mar; 34(3):341-7. PubMed ID: 21124329
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.
Saka M; Obata K; Ichihara S; Cheng XW; Kimata H; Noda A; Izawa H; Nagata K; Yokota M
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1164-71. PubMed ID: 17184496
[TBL] [Abstract][Full Text] [Related]
3. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
Kudo H; Kai H; Kajimoto H; Koga M; Takayama N; Mori T; Ikeda A; Yasuoka S; Anegawa T; Mifune H; Kato S; Hirooka Y; Imaizumi T
Hypertension; 2009 Oct; 54(4):832-8. PubMed ID: 19704105
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats.
Bezerra DG; Mandarim-de-Lacerda CA
Clin Sci (Lond); 2005 Apr; 108(4):349-55. PubMed ID: 15610072
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats.
Zhai Y; Gao X; Wu Q; Peng L; Lin J; Zuo Z
Eur J Pharmacol; 2008 Jun; 587(1-3):196-203. PubMed ID: 18430418
[TBL] [Abstract][Full Text] [Related]
6. Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats.
Li X; Han J; Li L; Wang KJ; Hu SJ
Int J Cardiol; 2013 Oct; 168(4):3340-7. PubMed ID: 23664044
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
[TBL] [Abstract][Full Text] [Related]
8. Large blood pressure variability and hypertensive cardiac remodeling--role of cardiac inflammation.
Kai H; Kudo H; Takayama N; Yasuoka S; Kajimoto H; Imaizumi T
Circ J; 2009 Dec; 73(12):2198-203. PubMed ID: 19875896
[TBL] [Abstract][Full Text] [Related]
9. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2005; 32(1-2):76-85. PubMed ID: 15730439
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats.
Chen HJ; Yao L; Chen TG; Yu M; Wang LH; Chen JZ
Chin Med J (Engl); 2007 Nov; 120(21):1902-7. PubMed ID: 18067764
[TBL] [Abstract][Full Text] [Related]
11. Baroreflex deficit blunts exercise training-induced cardiovascular and autonomic adaptations in hypertensive rats.
Moraes-Silva IC; De La Fuente RN; Mostarda C; Rosa K; Flues K; Damaceno-Rodrigues NR; Caldini EG; De Angelis K; Krieger EM; Irigoyen MC
Clin Exp Pharmacol Physiol; 2010 Mar; 37(3):e114-20. PubMed ID: 19930428
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.
Ye Y; Mou Y; Bai B; Li L; Chen GP; Hu SJ
Int J Biochem Cell Biol; 2010 Dec; 42(12):2056-64. PubMed ID: 20884373
[TBL] [Abstract][Full Text] [Related]
13. Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats.
Li L; Chen GP; Yang Y; Ye Y; Yao L; Hu SJ
Biochem Pharmacol; 2010 Feb; 79(3):399-406. PubMed ID: 19800872
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats.
Geng J; Zhao Z; Kang W; Wang W; Zhang Y; Zhiming GE
Pharmacol Res; 2010 Jan; 61(1):40-7. PubMed ID: 19683055
[TBL] [Abstract][Full Text] [Related]
15. The effect of diet on simvastatin and losartan enhancement of endothelial function.
Bayorh MA; Layas MF; Mann G; Feuerstein GZ; Eatman D
Clin Exp Hypertens; 2007 Jul; 29(5):311-25. PubMed ID: 17653966
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats.
Chamorro V; Wangensteen R; Sainz J; Duarte J; O'Valle F; Osuna A; Vargas F
Clin Sci (Lond); 2004 Mar; 106(3):251-9. PubMed ID: 14521506
[TBL] [Abstract][Full Text] [Related]
17. Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
Lu JC; Cui W; Zhang HL; Liu F; Han M; Liu DM; Yin HN; Zhang K; Du J
Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1110-9. PubMed ID: 19413592
[TBL] [Abstract][Full Text] [Related]
18. Cardoguard, an Ayurvedic antihypertensive formulation, prevents cardiac remodeling in spontaneously hypertensive rats by inhibition of ERK and PKCε signaling pathways.
Sankar V; Nair RR; Harikrishnan VS; Fernandez AC; Kumar CS; Madhavachandran V
Can J Physiol Pharmacol; 2012 May; 90(5):627-35. PubMed ID: 22550975
[TBL] [Abstract][Full Text] [Related]
19. Chronic absence of baroreceptor inputs prevents training-induced cardiovascular adjustments in normotensive and spontaneously hypertensive rats.
Ceroni A; Chaar LJ; Bombein RL; Michelini LC
Exp Physiol; 2009 Jun; 94(6):630-40. PubMed ID: 19251981
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats.
Loch D; Levick S; Hoey A; Brown L
J Cardiovasc Pharmacol; 2006 Mar; 47(3):396-404. PubMed ID: 16633082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
